Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Wachovia Downgrades Resmed to Market Perform

From Standard & Poor's Equity Research

Wachovia Securities downgraded its investment recommendation on shares of Resmed (RMD) to market perform from outperform.

Analyst Michael Matson says further deceleration in the company's revenue growth over the next three quarters could result in estimate misses and restrain the share price. Matson says he models revenue growth rates of 23% for the first quarter, 23% for the second, 20% for the third, respectively, against year ago's 45%, 41%, 50% growth rates. He cites the end of inorganic growth contribution from the Saime acquisition, tougher competition from Respironics (RESP) in flow generators and, to a lesser extent, masks, as well as the risk that the now-ended German strikes hurt sales. Matson believes investors interested in sleep apnea space would do better with Respironics.

blog comments powered by Disqus